Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK) released earnings for its full year that Increased, from last year
The company's earnings totaled RMB173.20 million, or RMB0.43 per share. This compares with RMB33.54 million, or RMB0.08 per share, last year.
The company's revenue for the period rose 40.6% to RMB1.379 billion from RMB980.45 million last year.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB173.20 Mln. vs. RMB33.54 Mln. last year.-EPS: RMB0.43 vs. RMB0.08 last year.-Revenue: RMB1.379 Bln vs. RMB980.45 Mln last year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.